NCT07447570 2026-03-03
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
Second Affiliated Hospital, School of Medicine, Zhejiang University
Akeso
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
UNICANCER
Maria Sklodowska-Curie National Research Institute of Oncology
Sun Yat-sen University
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's